Results from the REVISIT trial show aztreonam-avibactam had similar cure rates as meropenem in patients with serious ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by the drug major Pfizer to ...

New Delhi: The drug major Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase 2A clinical study ...

Treatment options for metallo-β-lactamases are restricted to non-β-lactam antibiotics, cefiderocol, or the combination of ceftazidime–avibactam and aztreonam. 2 Aztreonam is stable against ...

This week, a phase 3 clinical trial showed aztreonam-avibactam might be treatment option for patients facing multidrug-resistant infections. Meanwhile, research shows that penicillin allergies in ...

based on the results of the earlier TARGET study which showed non-inferiority for the drug compared to vancomycin plus aztreonam. If it gets a green light, it will be the first antibiotic in the ...

Amikacin VHA Plus 112180 1000 mg (100 mg/mL) in 0.45% sodium chloride injection SP 0.4 mL/min Aztreonam Bristol-Myers Squibb 9H28459 2 g (200 mg/mL) in 0.45% sodium chloride injection SP 0.4 mL ...

A Clinical and Laboratory Standards Institute-endorsed method (ie, broth disk elution method) to test for activity of the combination of ceftazidime-avibactam and aztreonam for MBL-producing ...

aeruginosa infection can often receive adequate MSSA coverage with antipseudomonal agents (with the exception of ceftazidime and aztreonam). The intravenous options for MRSA are generally limited ...

A Clinical and Laboratory Standards Institute-endorsed method (ie, broth disk elution method) to test for activity of the combination of ceftazidime-avibactam and aztreonam for MBL-producing ...

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held ...